Skip to content
CFPS Research Archives

Teriparatide (Forteo)

FDA-approved context Muscle & Bone Health 2 sources

Teriparatide is a recombinant form of parathyroid hormone (PTH 1-34) that stimulates new bone formation. It is FDA-approved for the treatment of osteoporosis in men and women at high risk for fracture, acting as an anabolic agent rather than just an antiresorptive one.

01Dosing reference

Amount
20 mcg
Frequency
Once daily
Cycle
Up to 24 months lifetime duration
Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

01

PTH1 receptor activation

Teriparatide binds to the parathyroid hormone 1 (PTH1) receptor on osteoblasts and osteocytes.

02

Osteoblast stimulation

Intermittent administration stimulates osteoblast activity over osteoclast activity, promoting bone formation.

03

Increased bone mineral density

This leads to increased bone mass, improved bone microarchitecture, and reduced fracture risk.

03Human evidence

Significant reduction in vertebral and nonvertebral fractures.

Large randomized controlled trials in postmenopausal women with osteoporosis showed a 65% reduction in vertebral fractures over 19 months.

Increased bone mineral density (BMD) in men with primary or hypogonadal osteoporosis.

Clinical trials demonstrated significant increases in lumbar spine and femoral neck BMD compared to placebo.

04Preclinical evidence

Enhanced fracture healing and callus formation.

Animal models of fracture healing showed accelerated bridging and increased biomechanical strength of the healing bone.

Reversal of bone loss in ovariectomized rats.

Rodent models of postmenopausal osteoporosis demonstrated restoration of trabecular bone volume and connectivity.

05What is known vs. unknown

Reasonably established
  • Teriparatide is an anabolic bone agent, meaning it builds new bone rather than just slowing bone loss.
  • It is administered via daily subcutaneous injection.
  • It is highly effective at reducing the risk of vertebral and nonvertebral fractures in severe osteoporosis.
  • The maximum recommended lifetime duration of treatment is typically 24 months.
Unknowns & limits
  • The long-term effects beyond 24 months of use are not fully established, leading to the recommended treatment duration limit.
  • While it increases bone density, the optimal sequential therapy (e.g., following it with an antiresorptive agent) is still being refined to maintain the bone gains.

06Safety & regulatory context

Regulatory statusTeriparatide is FDA-approved for osteoporosis in postmenopausal women and men at high risk of fracture, and for glucocorticoid-induced osteoporosis. It previously carried a black box warning for osteosarcoma based on rat studies, but this was removed by the FDA in 2020 after long-term human data showed no increased risk. Common side effects include nausea, dizziness, leg cramps, and injection site reactions. It is contraindicated in patients with Paget's disease of bone, unexplained elevations of alkaline phosphatase, or prior skeletal radiation therapy.

07Compared with Abaloparatide (Tymlos)

Teriparatide (Forteo) vs. Abaloparatide (Tymlos)
Key difference
Abaloparatide is a synthetic analog of PTH-related protein (PTHrP) that binds more selectively to the RG conformation of the PTH1 receptor, potentially causing less bone resorption and hypercalcemia than teriparatide.
When researchers discuss each
Teriparatide is discussed as the classic, first-in-class anabolic agent for severe osteoporosis, while abaloparatide is discussed as a newer alternative that may offer a slightly different safety and efficacy profile, particularly regarding hypercalcemia.

08Glossary

Osteoblast
A cell that secretes the matrix for bone formation.
Osteoclast
A type of bone cell that breaks down bone tissue.
Anabolic agent
A substance that promotes tissue growth, in this case, building new bone.
Antiresorptive
Medications that slow or stop the natural process that dissolves bone tissue.

09Knowledge check

Q1How does teriparatide primarily differ from bisphosphonates in treating osteoporosis?
Q2Why is intermittent (daily) administration of teriparatide crucial for its therapeutic effect?
Q3When interpreting the clinical evidence for teriparatide, which statement best reflects a documented limitation in the dossier?
Q4According to the dossier’s comparison with abaloparatide, which difference is presented as a potential advantage of abaloparatide over teriparatide?
Q5Which regulatory or safety statement about teriparatide is supported by the dossier?

10Sources

More in Muscle & Bone Health

See all

IGF-1 LR3

Muscle & Bone Health
Early human

IGF-1 LR3 is a synthetic, modified version of Insulin-like Growth Factor-1 with an extended half-life and increased potency. Research highlights its ability to promote muscle cell hyperplasia (growth of new muscle cells), enhance protein synthesis, and improve recovery by resisting deactivation by IGF-binding proteins.

20-50 mcg per day

GDF-8 Myostatin Inhibitor

Muscle & Bone Health
Early human

GDF-8 (Growth Differentiation Factor 8), commonly known as myostatin, is a protein that naturally inhibits muscle growth. Myostatin inhibitors are compounds designed to block this protein, thereby promoting significant muscle hypertrophy and preventing muscle wasting in various research models.

1 mg - 3 mg (highly variable depending on specific peptide/antibody)

ACE-031

Muscle & Bone Health
Early human

ACE-031 is an investigational protein therapeutic designed to build muscle and increase strength by inhibiting signaling through the activin receptor type IIB (ActRIIB). Research primarily focused on its potential to treat muscle-wasting diseases like Duchenne muscular dystrophy, though clinical trials were halted due to safety concerns involving bleeding.

1-3 mg/kg (in clinical trial settings)
Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.